Private biotech Eyevensys said today that it treated the 1st patient in a first-in-human phase I/II trial of its lead candidate, EYS606, for the treatment of non-infectious uveitis. The patient was treated in Paris at the Cochin Institute using the company’s EyeCET technology.
The EyeCET platform is an electro-transfection injection system that delivers non-viral plasmids to encode for disease-specific therapeutic proteins in the ciliary muscle of the eye. Eyevensys’ lead product delivers a plasmid that encodes for the production of a protein to treat non-infectious uveitis.
Get the full story at our sister site, Drug Delivery Business News.